Effects of psilocybin with psychological support on anhedonia in treatment-resistant depression
Primary Objective
This study is examining the effects of psilocybin along with psychological support on treatment-resistant depression. Specifically, the study seeks to understand psilocybin's effects on anhedonia, a common symptom of major depressive disorder that refers to an individual's loss of ability to feel excitement, motivation, or pleasure.
Description
Participants will be randomly assigned to receive either active psilocybin or placebo. Participation in the study will last a minimum of 13 weeks, up to a maximum of 26 weeks. The study will involve completion of a physical exam, blood draw, two MRI scans, surveys and psychological assessments, and weekly study visits. Certain medications may need to be stopped during the trial.
Details
Locations
Brain Imaging Center (BIC)
Outpatient CTRC
Principal Investigator
Andrew Novick
Study ID
Protocol Number: 22-1681
More information available at ClinicalTrials.gov: NCT06230757
Categories
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers